Obesity Featured Articles

  1. Why Clinical And Commercial Development Must Be Integrated Fully And Early For FDA And Reimbursement Success 4/6/2026

    With clear alignment among clinical development, regulatory, and commercial development processes, sponsor companies can better prepare for FDA approval and successful Medicare reimbursement.

  2. With A Clear Focus And Promising Asset, Crystalys Is Skipping Phase 2 Trials For Gout 4/3/2026

    Crystallis President and CEO James Mackay shares insights from the company’s clinical decision-making for dotinurad, including the inclusion of an open label extension. 

  3. RWD Helps Researchers Include More Patients In Lymphoma Research 4/2/2026

    Andrew Evens, DO, MBA, explores how outcomes research and collaboration across academic networks, registries, and industry partners are advancing more inclusive, data-informed approaches to lymphoma research.

  4. RWE Is Ready — Decision Making For Pharmaceuticals Isn't 4/1/2026

    Gorana Capkun of Merck, KGaA, Darmstadt, Germany discusses the growing role of real-world evidence in clinical trials, highlighting a gap between regulatory momentum and pharma adoption— and the challenge of turning data into better decisions.

  5. Paper COAs In 2026? It's Not "Cheaper," It's Riskier 4/1/2026

    Paper-based assessments add operational and regulatory risk — from poor data quality to delayed insights — quietly threatening timelines, compliance, and trial confidence.

  6. Could Study Rehearsals Create A New Standard For Site Readiness? 4/1/2026

    Giving sites the chance to rehearse a trial ahead of their initial study visits could lead to improved readiness, protocol adherence, and participant experience.

  7. Strategies To Win Breakthrough Designation In Rare Disease Programs 3/31/2026

    Breakthrough designation can unlock faster paths for rare disease therapies. Learn how smart timing, compelling evidence, and early regulatory alignment can turn promising science into accelerated patient impact.

  8. 5 Strategies For Designing Successful Complex Rare Disease Trials 3/31/2026

    Rare disease trials demand inventive design. Uncover creative strategies that help sponsors overcome tiny populations, complex endpoints, and operational hurdles to advance meaningful breakthroughs.

  9. 5 RWE Approaches That Strengthen Precision Oncology 3/31/2026

    Real-world evidence is becoming vital in precision oncology. Discover five creative, practical ways sponsors can use RWE to fuel development, sharpen regulatory strategy, and strengthen market access.

  10. Which FIH Decisions Are Hardest To Reverse Later? 3/31/2026

    Early oncology trial decisions can lock in risk, shape regulatory confidence, and limit flexibility. Knowing which choices are hardest to reverse protects optionality and credibility.